The latest price target for scPharmaceuticals (NASDAQ:SCPH) was reported by HC Wainwright & Co. on November 14, 2024. The analyst firm set a price target for $18.00 expecting SCPH to rise to within 12 months (a possible 427.86% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for scPharmaceuticals (NASDAQ:SCPH) was provided by HC Wainwright & Co., and scPharmaceuticals reiterated their buy rating.

The last upgrade for scPharmaceuticals Inc happened on October 11, 2022 when SVB Leerink raised their price target to $11. SVB Leerink previously had a market perform for scPharmaceuticals Inc.

There is no last downgrade for scPharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of scPharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for scPharmaceuticals was filed on November 14, 2024 so you should expect the next rating to be made available sometime around November 14, 2025.

While ratings are subjective and will change, the latest scPharmaceuticals (SCPH) rating was a reiterated with a price target of $18.00 to $18.00. The current price scPharmaceuticals (SCPH) is trading at is $3.41, which is out of the analyst’s predicted range.